Member Info for mbingo

Very quiet here. What’s the XTR site? The company looking to address funding gap. I remain underwater with average in the late 7s. Expecting resolution in the next couple of weeks and half yearly numbers.

Background buyer requiring higher prices for investors to release stock. Hold/buy - all being well, should re-test recent highs and break up through 1p. After all, they are positioned to benefit from return of elective surgeries in the US. Hospitals in US lost out on $20bn+ in revenues in 2020. They need to increase elective surgeries to re-balance the books and there is big demand/backlog. This is £50m cap with cash/inventory at £15m+.

It’s about 20% of my portfolio (about 9m shares). I can see the upside. No debt or cash flow concerns. It’s very cheap at £40-45m. What holds them back is the share count which is 7.5bn in issue due to the poor raise last year - but as the turnaround story develops, shares will move to tighter hands. I hope that this happens sooner rather than later. Also, as majority revenue comes out of the US, if the USD strengthens, it reflects positively in GBP which acts as a hedge around other positions.

I picked up another 750k today. Its a bargain ??! Serious upside from these levels imo hence why my largest position - and frankly quite off the radar even after the CEO/CFO/non-exec buys.

Fantastic, great show of support from the board.

Barely more ...!

Tissue Regenix will catch a bid at some stage. Elective surgery demand is clearly there, US opening up, board have been buying (higher than current levels). I like this share at Barry more than £40m cap with sufficient cash to see them through next year and no debt - plus new revenue streams.

I would have thought so. There are catalysts aplenty for Tissue Regenix with lowly valuation. Amazing that we’ve had buys from chairman, CFO and CEO, the last two above today’s prices - and valuation lingers below these levels. World ex U.K. is opening up. Massive backlog for elective surgeries. TRX will catch a bid at some stage...

Not sure, but should reignite interest in the equity! Also, BGF Investments intentions unclear. They took a 5.1% stake recently. Strikes me that their positions are usually bigger - are they still building? What is their plan!?

Agree, think there is a lot of value here at £42m cap. Would be good to get an update on the morrissons shift. Clearly, performance significantly better on the 30 Morrison daily stores - and Uber eats. A move in margin on Revenue at more than £1.2bn should see a big swing here to the upside. Not going to happen overnight of course, but risk v reward very attractive to me at £42m cap valuation.

They are mid-term elections. If it’s a tight race, think it bodes well. A convincing win for the man in power and this is less good. Nothing will happen quickly though in terms of change of policy IMO

10% less than the CEOs buy and 5% less than the CFOs buys of last week. I added a few.

https://www.hardmanandco.com/wp-content/uploads/2020/10/TRX-post-interims-update-–-7-Oct-2020.pdf

From October last year, worth reading.

There are a lot of shares in issue. Some of the holders taking profit from the extreme lows. £40m cap covers a lot - cash (£8-9m), inventory (£7m), FDA and CE approved products, revenue at £13m, infrastructure upgrade and potential to take that to £30m at phase 2 completion, white label product with J&J (rumoured but visible in videos of marketing), two new products to be launched this year (per CEO discussion on Wednesday). Elective surgeries will go through the roof - lots of people need operations so will be huge demand for their products. Do your own research !! But very little downside and major upside potential is my take. I write more in my Twitter feed @mbingo. Chairman bought a few in Jan/Feb. Hope the new CEO will buy too. Lombard Odier added a few more too.

It was RNS’d

Two new products coming online this year.

The £40m cap clearly a nonsense given products, revenue and relationships. Cash to take them them through to self sustaining profit. Inventory impressive.

Yes, CEO said that he may look at M&A or could actually be an acquisition target.

104k last year - my bad.

Do you know the scale up plan? They did about 90k last year and plan on 100k this year. It’s as much about AISC control also, keeping costs under control.